glp-1 weight loss type 1 diabetes Medications for Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness Improved Heart and Kidney Outcomes

As these peoples dietary habits shift, it leads to a decline in caloric intake and an increased focus on portion control

While injectability remains common, oral, transdermal, and implantable delivery strategies are increasingly viable for selected peptides (Fosgerau and Hoffmann, 2015)

Become a paid subscriber!

This is significant, considering that data from Blue Cross Blue Shield found that over 63% of GLP-1 patients from 2014 to 2023 were in this age group

Retatrutide is a groundbreaking triple agonist currently in Phase 3 trials that is redefining what is possible without surgery: Triple-Action Mechanism: Unlike Wegovy (1 receptor) or Zepbound (2 receptors), Retatrutide targets three hormones: GLP-1, GIP, and Glucagon

Many women report meaningfully different hunger suppression patterns on retatrutide compared to tirzepatide, with particularly strong effects on food reward and cue-triggered eating rather than just basal appetite